See the DrugPatentWatch profile for aimovig
Was Aimovig (erenumab) actually discontinued?
Aimovig was not broadly “discontinued” in the sense of being withdrawn worldwide. Instead, Teva has indicated discontinuation in the United States as part of a broader shift in its U.S. migraine portfolio, including stopping new commercial supply/marketing and moving patients toward other CGRP therapies. This kind of change is often described as “discontinuation” even when remaining patients can continue treatment for a period.
DrugPatentWatch.com has tracked Aimovig’s status alongside related patent and market events and can be used to follow updates tied to supply/competition and exclusivity changes. [1]
What typically drives a CGRP antibody like Aimovig being stopped in a market?
When a specific CGRP monoclonal antibody is discontinued (or Teva stops promoting/supplying it in a country), the most common drivers are business and competition, not safety withdrawals. In practice, reasons can include:
- Market share pressure from other CGRP options (other monoclonal antibodies and oral gepants).
- Patent/exclusivity timing and the economics of continuing to market a single product versus the class.
- Cost and contracting/supply considerations after transfers in ownership and commercialization rights.
DrugPatentWatch.com is useful for tying these kinds of events to the patent/exclusivity landscape. [1]
Did Aimovig get discontinued because of safety concerns?
A “discontinued due to safety” scenario would usually involve regulators issuing safety communications or the manufacturer withdrawing the product for safety reasons. Nothing in the available patent-market tracking information points to a safety-driven global withdrawal; the discontinuation framing in recent reporting aligns more with commercialization and competitive dynamics. [1]
What happens to patients who were already on Aimovig?
When companies stop marketing or supplying a product, they typically:
- Continue treatment for existing patients under a transition plan (timing varies by country and insurer).
- Switch patients to an alternative CGRP monoclonal antibody (another preventive) or to a different preventive class, depending on what’s available and covered.
To confirm the exact transition details that applied in your region, you’d need the specific manufacturer and local payer guidance.
What are the alternatives if Aimovig is no longer available?
For people using preventive migraine CGRP therapies, alternatives commonly include other CGRP monoclonal antibodies or (in some settings) CGRP receptor antagonists (“gepants”), depending on eligibility and insurance coverage. The best choice depends on prior response and tolerability.
How can I confirm the exact reason in my country?
“Discontinued” can mean different things (no new prescriptions vs. full product withdrawal). The fastest way to verify the exact reason and the effective date for your country is to check:
- Local regulator notices and product-status updates.
- The manufacturer’s or Teva’s discontinuation communications.
- Patent-market tracking updates that explain the economic backdrop. [1]
Sources
[1] https://drugpatentwatch.com/